Porcelli L - Search Results

1

Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.

Serratì S, Di Fonte R, Porcelli L, De Summa S, De Risi I, Fucci L, Ruggieri E, Marvulli TM, Strippoli S, Fasano R, Rafaschieri T, Guida G, Guida M, Azzariti A. Serratì S, et al. Among authors: porcelli l. J Exp Clin Cancer Res. 2023 Sep 28;42(1):251. doi: 10.1186/s13046-023-02808-9. J Exp Clin Cancer Res. 2023. PMID: 37759291 Free PMC article.

2

Which role for EGFR therapy in breast cancer?

Lorusso V, Forcignano R, Cinieri S, Tinelli A, Porcelli L, Quatrale AE, Chiuri VE. Lorusso V, et al. Among authors: porcelli l. Front Biosci (Schol Ed). 2012 Jan 1;4(1):31-42. doi: 10.2741/s249. Front Biosci (Schol Ed). 2012. PMID: 22202041 Free article. Review.

3

The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).

Azzariti A, Xu JM, Porcelli L, Paradiso A. Azzariti A, et al. Among authors: porcelli l. Biochem Pharmacol. 2004 Jul 1;68(1):135-44. doi: 10.1016/j.bcp.2004.03.014. Biochem Pharmacol. 2004. PMID: 15183125

4

Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.

Giannelli G, Azzariti A, Fransvea E, Porcelli L, Antonaci S, Paradiso A. Giannelli G, et al. Among authors: porcelli l. Br J Cancer. 2004 Nov 29;91(11):1964-9. doi: 10.1038/sj.bjc.6602231. Br J Cancer. 2004. PMID: 15545972 Free PMC article.

5

ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells.

Giannelli G, Azzariti A, Sgarra C, Porcelli L, Antonaci S, Paradiso A. Giannelli G, et al. Among authors: porcelli l. Biochem Pharmacol. 2006 Feb 14;71(4):479-85. doi: 10.1016/j.bcp.2005.11.005. Epub 2005 Dec 5. Biochem Pharmacol. 2006. PMID: 16332356

6

Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.

Azzariti A, Porcelli L, Xu JM, Simone GM, Paradiso A. Azzariti A, et al. Among authors: porcelli l. World J Gastroenterol. 2006 Aug 28;12(32):5140-7. doi: 10.3748/wjg.v12.i32.5140. World J Gastroenterol. 2006. PMID: 16937523 Free PMC article.

7

Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells.

Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A. Azzariti A, et al. Among authors: porcelli l. Biochem Pharmacol. 2008 Mar 1;75(5):1035-44. doi: 10.1016/j.bcp.2007.11.018. Epub 2007 Dec 3. Biochem Pharmacol. 2008. PMID: 18191814

8

EGFR and VEGFR as potential target for biological therapies in HCC cells.

Giannelli G, Sgarra C, Porcelli L, Azzariti A, Antonaci S, Paradiso A. Giannelli G, et al. Among authors: porcelli l. Cancer Lett. 2008 Apr 18;262(2):257-64. doi: 10.1016/j.canlet.2007.12.001. Epub 2008 Jan 11. Cancer Lett. 2008. PMID: 18248788

9

Intracellular trafficking of MDR transporters and relevance of SNPs.

Porcelli L, Lemos C, Peters GJ, Paradiso A, Azzariti A. Porcelli L, et al. Curr Top Med Chem. 2009;9(2):197-208. doi: 10.2174/156802609787521562. Curr Top Med Chem. 2009. PMID: 19200005 Review.

10

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.

Azzariti A, Porcelli L, Simone GM, Quatrale AE, Colabufo NA, Berardi F, Perrone R, Zucchetti M, D'Incalci M, Xu JM, Paradiso A. Azzariti A, et al. Among authors: porcelli l. Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46. doi: 10.1007/s00280-009-1039-0. Cancer Chemother Pharmacol. 2010. PMID: 19495754

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters